CA
NZ
UK
AU
IND
US
…
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on vTv Therapeutics is limited; historically it operated as a small clinical-stage biotechnology company focused on therapies for metabolic and central nervous system disorders. Long-term growth drivers depend on clinical progress of any remaining pipeline programs, successful licensing or partnership transactions, and access to capital to advance development. Investors may find potential upside if programs show clinical efficacy or attract partners, but available information is sparse and progress has been uneven.
Key risks include clinical and regulatory failure, limited public disclosure and liquidity, and significant financing and dilution risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -24.87M | -17.62M | -12.80M | -21.84M | -23.64M |
| Minority interest | -5.91M | 4.74M | -4.30M | 40.18M | 62.48M |
| Net income | -25.07M | -17.73M | -8.83M | -21.94M | -7.91M |
| Selling general administrative | 12.20M | 12.34M | 7.25M | 8.54M | 9.22M |
| Gross profit | 2.02M | 4.00M | 6.41M | 2.76M | 12.43M |
| Reconciled depreciation | 0.09M | 0.09M | 0.09M | 0.04M | 0.22M |
| Ebit | -22.54M | -21.66M | -11.85M | -20.89M | -20.57M |
| Ebitda | -24.86M | -17.60M | -12.11M | -20.01M | -20.36M |
| Depreciation and amortization | -2.32M | 4.06M | -0.26M | 0.88M | 0.22M |
| Non operating income net other | -3.26M | - | 0.01M | 0.05M | - |
| Operating income | -22.54M | -21.66M | -11.85M | -20.89M | -19.82M |
| Other operating expenses | 24.56M | 25.67M | 18.27M | 23.66M | 32.26M |
| Interest expense | 0.01M | 0.01M | 0.69M | 1.83M | 3.29M |
| Tax provision | 0.20M | 0.12M | 0.00M | 0.10M | 0.20M |
| Interest income | 0.35M | 0.00M | 0.01M | 0.05M | 0.06M |
| Net interest income | 0.34M | -0.01M | -0.68M | -1.77M | -3.23M |
| Income tax expense | 0.20M | 0.12M | -3.98M | 0.10M | 0.20M |
| Total revenue | 2.02M | 4.00M | 6.41M | 2.76M | 12.43M |
| Total operating expenses | 24.56M | 25.67M | 18.27M | 23.66M | 32.26M |
| Cost of revenue | - | - | - | 15.12M | 23.04M |
| Total other income expense net | -2.33M | 4.05M | -0.95M | -0.95M | -0.59M |
| Net income from continuing ops | -25.07M | -17.73M | -12.80M | -21.94M | -23.84M |
| Net income applicable to common shares | -19.16M | -12.99M | -8.50M | -17.91M | -8.65M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11.02M | 33.24M | 25.47M | 14.79M | 9.27M |
| Other current assets | 1.11M | 2.54M | 2.05M | 0.94M | 0.81M |
| Total liab | 29.57M | 43.98M | 35.21M | 94.89M | 58.29M |
| Total stockholder equity | -24.68M | -10.74M | -9.74M | -80.10M | -49.02M |
| Other current liab | 6.17M | 4.85M | 8.06M | 4.20M | 4.84M |
| Common stock | 0.03M | 1.05M | 0.90M | 0.77M | 0.64M |
| Capital stock | 0.03M | 1.05M | 0.90M | 0.77M | 0.64M |
| Retained earnings | -281.04M | -265.52M | -248.83M | -290.04M | -233.52M |
| Other liab | - | 19.35M | 1.26M | 3.93M | 3.89M |
| Other assets | - | - | - | 7.21M | 2.94M |
| Cash | 9.45M | 12.13M | 13.41M | 5.75M | 1.78M |
| Total current liabilities | 10.62M | 7.71M | 8.50M | 6.39M | 13.38M |
| Current deferred revenue | 0.02M | 0.02M | 0.04M | 0.03M | 0.03M |
| Net debt | -8.92M | -11.41M | -12.48M | -4.83M | 5.34M |
| Short term debt | 0.36M | 0.38M | 0.44M | 0.24M | 6.28M |
| Short long term debt | 0.19M | 0.22M | 0.26M | 0.08M | 6.17M |
| Short long term debt total | 0.53M | 0.72M | 0.93M | 0.92M | 7.11M |
| Other stockholder equity | 256.33M | 253.74M | 238.19M | 209.16M | 183.86M |
| Property plant equipment | - | 0.21M | 0.68M | 0.37M | 1.00M |
| Total current assets | 10.66M | 27.09M | 15.62M | 7.21M | 2.84M |
| Long term investments | 0.00M | 5.59M | 9.17M | 6.72M | 2.48M |
| Net tangible assets | - | 5.84M | -9.74M | 3.79M | -49.02M |
| Short term investments | 0.07M | - | - | 6.72M | 0.25M |
| Net receivables | 0.10M | 12.42M | 0.06M | 0.16M | 0.01M |
| Inventory | - | 0.01M | 0.10M | 0.37M | 0.25M |
| Accounts payable | 4.08M | 2.46M | 8.02M | 6.12M | 7.07M |
| Accumulated other comprehensive income | - | - | - | - | -0.15M |
| Common stock total equity | - | 1.05M | - | 0.54M | 0.64M |
| Retained earnings total equity | - | -265.52M | - | -290.04M | -233.52M |
| Non currrent assets other | - | 0.35M | - | -6.72M | 2.94M |
| Non current assets total | 0.36M | 6.14M | 9.85M | 7.57M | 6.43M |
| Capital lease obligations | 0.34M | 0.49M | 0.68M | 0.83M | 0.94M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.02M | 0.00M | 0.00M | 0.24M | 0.01M |
| Change to liabilities | -0.86M | 0.82M | -1.21M | -0.62M | -6.23M |
| Total cashflows from investing activities | -0.02M | -0.02M | -0.02M | 0.24M | 0.01M |
| Net borrowings | -0.03M | 0.17M | -4.96M | -10.07M | -4.89M |
| Total cash from financing activities | 14.75M | 26.98M | 19.47M | 22.87M | 16.61M |
| Change to operating activities | -0.40M | -0.89M | -1.53M | 0.32M | 1.09M |
| Net income | -25.07M | -17.73M | -12.80M | -21.94M | -23.84M |
| Change in cash | -1.29M | 7.67M | 1.47M | 0.09M | -10.24M |
| Begin period cash flow | 13.41M | 5.75M | 4.28M | 4.18M | 14.42M |
| End period cash flow | 12.13M | 13.41M | 5.75M | 4.28M | 4.18M |
| Total cash from operating activities | -16.02M | -19.31M | -18.00M | -23.02M | -26.86M |
| Issuance of capital stock | 5.04M | 26.76M | 24.43M | 32.94M | 21.50M |
| Depreciation | 0.09M | 0.09M | 0.09M | 0.04M | 0.22M |
| Other cashflows from investing activities | - | - | - | 0.31M | 0.01M |
| Dividends paid | - | - | - | 0.99M | - |
| Change to inventory | - | -0.89M | -1.98M | 0.62M | - |
| Change to account receivables | -0.12M | 0.10M | -0.15M | -0.01M | 8.00M |
| Sale purchase of stock | 9.75M | - | 14.43M | 0.99M | 21.50M |
| Other cashflows from financing activities | 10.52M | 0.93M | 0.50M | 0.50M | 0.50M |
| Change to netincome | 4.50M | -6.45M | 1.01M | 1.23M | 2.66M |
| Capital expenditures | 0.02M | 0.02M | 0.02M | 0.07M | 0.01M |
| Change receivables | -0.12M | - | -0.15M | -0.01M | 8.00M |
| Cash flows other operating | 5.43M | - | -5.32M | -2.26M | -8.68M |
| Cash and cash equivalents changes | -1.29M | - | 1.47M | 0.09M | -10.24M |
| Change in working capital | 5.38M | 0.04M | -2.71M | -2.05M | -7.54M |
| Stock based compensation | 1.27M | 2.36M | 1.01M | 1.52M | 2.68M |
| Other non cash items | 2.30M | -4.06M | 0.38M | 0.53M | 1.01M |
| Free cash flow | -16.04M | -19.31M | -18.00M | -23.09M | -26.86M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VTVT vTv Therapeutics Inc |
0.47 2.24% |
21.47 | - | - | 3631.36 | - | 3515.11 | -1.96 |
| NVO Novo Nordisk A/S |
0.41 1.00% |
41.10 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.86 0.16% |
547.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
43.35 4.73% |
959.41 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
3980 Premier Drive, High Point, NC, United States, 27265
336 841 0300
16
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul J. Sekhri M.Sc., MSc | CEO, Pres & Director | 1958 |
| Mr. Barry Brown | Chief Accounting Officer | 1961 |
| Dr. Carmen Valcarce Ph.D. | Chief Scientific Officer & Exec. VP | NA |
| Vanessa McDade | Chief Admin. Officer | NA |
| Mr. David M. Lambert III | Sr. VP & Gen. Counsel | NA |
| Mr. Richard S. Nelson | Exec. VP of Corp. Devel. & Director | 1970 |
| Mr. Paul J. Sekhri M.Sc. | CEO, President & Director | 1958 |
| Mr. Steven Tuch M.B.A. | Executive VP & CFO | 1969 |
| Mr. Richard S. Nelson | Executive VP of Corporate Development & Director | 1971 |
| Dr. Carmen Valcarce Ph.D. | Chief Scientific Officer & Executive VP | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.29%
Communication Services
+0.51%
Consumer Cyclical
-0.08%
Consumer Defensive
-0.14%
Energy
+1.08%
Financial Services
+0.14%
Financials
-0.06%
Healthcare
+0.51%
Industrials
+0.47%
Real Estate
-0.23%
Technology
+2.03%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...